Molecular diagnosis is a process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. Molecular diagnostic tests are used to detect specific sequences in DNA or RNA including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others. These are cumulative techniques for analyzing biological markers at the molecular level, such as genome and proteome. This technique is used for the diagnosis of various infectious diseases, cancer, and other genetic disorders.

The global molecular diagnostics market was valued at $5,962 million in 2016, and is estimated to garner $10,557 million by 2023, registering a CAGR of 9.1% during the forecast period of 2017-2023. The major factors enhancing the growth of this market include growth in number of patients suffering from infectious diseases and cancer; increase in awareness and acceptance for personalized medicine; advancement in molecular diagnostics; and rise in the biomarker identification market. However, stringent regulatory requirements for the product approval restrains the market growth.

The global molecular diagnostics market is segmented by type, technology, application, end user, and geography. Based on type, it is classified into instruments, reagents, and software & services. Based on technology, it is categorized into polymerase chain reaction (PCR), hybridization, DNA sequencing, microarray, isothermal nucleic acid amplification technology(INAAT), and others (electrophoresis, mass spectroscopy, and flow cytometry). Based on application, it is divided into infectious diseases, oncology, genetic testing, blood screening, and others (microbiology, neurological diseases, and cardiovascular diseases).

Based on end user, it is classified into hospitals, laboratories, and others (blood banks, home health agencies, and nursing homes). Geographically, it is analyzed based on four regions, namely, North America, Europe, Asia-Pacific, and LAMEA. The North America market accounted for significant share in the global market in 2016, owing to higher adoption rate for personalized medicine and increase in demand for technologically advanced molecular diagnostics for treating the patients suffering from different infectious diseases and cancer.

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global molecular diagnostics market and the current trends and future estimations to elucidate the imminent investment pockets.
The report provides quantitative analysis of the industry for the period of 2016-2023 to enable stakeholders to capitalize on the prevailing opportunities.
Extensive analysis of the market based on the type, technology, application, and end user elucidate the prevailing opportunities in these segments.
Comprehensive analysis of geographical regions is provided to determine the latent regional opportunities.
The key players operating in the market are profiled and their strategies to determine the competitive outlook of the market.

Molecular Diagnostics Market Key Segments:

BY PRODUCT

Instruments
Reagents
Software & Services

BY TECHNOLOGY

Polymerase Chain Reactions (PCR)
Hybridization
DNA Sequencing
Microarray
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others (Electrophoresis, Mass spectroscopy, and Flow cytometry)

BY APPLICATION

Infectious Diseases
Oncology
Genetic Testing
Microbiology
Blood Screening
Others (Microbiology, Neurological Diseases, and Cardiovascular Diseases)

BY END USER

Hospitals
Laboratories
Others (Blood Banks, Home Health Agencies, and Nursing Homes)

BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Abbott Laboratories, Inc.
BioMerieux SA
Becton, Dickinson and Company
Cepheid (subsidiary of Danaher Corporation)
Grifols
Hologic Corporation
Novartis AG
Qiagen N.V.
Siemens Healthcare GmbH
Roche Diagnostics

LIST OF OTHER PLAYERS IN THE VALUE CHAIN

(These players are not profiled in the report, but can be included on request)
Bayer Healthcare
Bio-Rad Laboratories
Johnson & Johnson
Dalko Diagnostics
Sysmex Corporation